JPWO2020081410A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020081410A5 JPWO2020081410A5 JP2021545267A JP2021545267A JPWO2020081410A5 JP WO2020081410 A5 JPWO2020081410 A5 JP WO2020081410A5 JP 2021545267 A JP2021545267 A JP 2021545267A JP 2021545267 A JP2021545267 A JP 2021545267A JP WO2020081410 A5 JPWO2020081410 A5 JP WO2020081410A5
- Authority
- JP
- Japan
- Prior art keywords
- radiolabeled compound
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- mammalian species
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 32
- 150000003839 salts Chemical class 0.000 claims 19
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 238000000034 method Methods 0.000 claims 13
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 claims 9
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 230000003176 fibrotic effect Effects 0.000 claims 7
- 238000002600 positron emission tomography Methods 0.000 claims 7
- 230000002285 radioactive effect Effects 0.000 claims 5
- 101000966782 Homo sapiens Lysophosphatidic acid receptor 1 Proteins 0.000 claims 3
- 102100040607 Lysophosphatidic acid receptor 1 Human genes 0.000 claims 3
- 238000003384 imaging method Methods 0.000 claims 3
- 238000011503 in vivo imaging Methods 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862745524P | 2018-10-15 | 2018-10-15 | |
| US62/745,524 | 2018-10-15 | ||
| PCT/US2019/056033 WO2020081410A2 (en) | 2018-10-15 | 2019-10-14 | Radioligands for imaging the lpa1 receptor |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022508699A JP2022508699A (ja) | 2022-01-19 |
| JP2022508699A5 JP2022508699A5 (https=) | 2022-08-30 |
| JPWO2020081410A5 true JPWO2020081410A5 (https=) | 2022-08-30 |
| JP7367038B2 JP7367038B2 (ja) | 2023-10-23 |
Family
ID=70284132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021545267A Active JP7367038B2 (ja) | 2018-10-15 | 2019-10-14 | Ｌｐａ１受容体のイメージングのための放射性リガンド |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20210379210A1 (https=) |
| EP (1) | EP3866692B1 (https=) |
| JP (1) | JP7367038B2 (https=) |
| KR (1) | KR102923704B1 (https=) |
| CN (1) | CN113260310A (https=) |
| AU (1) | AU2019362770B2 (https=) |
| CA (1) | CA3116129A1 (https=) |
| ES (1) | ES3037591T3 (https=) |
| SG (1) | SG11202103731QA (https=) |
| WO (1) | WO2020081410A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111434653A (zh) | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 三氮唑类化合物及其制备方法与用途 |
| CN111434655A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 溶血磷脂酸受体拮抗剂及其制备方法 |
| AU2020384883B2 (en) | 2019-11-15 | 2023-11-16 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| CN115867556B (zh) | 2020-06-03 | 2025-05-06 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| TWI853704B (zh) | 2021-05-11 | 2024-08-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| KR20240007233A (ko) | 2021-05-13 | 2024-01-16 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| WO2023107938A1 (en) | 2021-12-08 | 2023-06-15 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| CN121866249A (zh) * | 2023-09-08 | 2026-04-14 | 海思科医药集团股份有限公司 | 一种lpar1拮抗剂及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI618544B (zh) | 2006-12-26 | 2018-03-21 | 藍瑟斯醫學影像公司 | 使心臟神經分布顯像之配位體 |
| US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| GB201203793D0 (en) | 2012-03-05 | 2012-04-18 | Ge Healthcare Ltd | Imaging neural activity |
| WO2015066456A1 (en) | 2013-10-31 | 2015-05-07 | Bristol-Myers Squibb Company | Radioligands for imaging the lpa-1 receptor |
| US10994033B2 (en) * | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| EP4011875A1 (en) * | 2017-12-19 | 2022-06-15 | Bristol-Myers Squibb Company | Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| EA202091505A1 (ru) * | 2017-12-19 | 2020-09-22 | Бристол-Маерс Сквибб Компани | Триазолазолы циклогексильной кислоты в качестве антагонистов lpa |
-
2019
- 2019-10-14 SG SG11202103731QA patent/SG11202103731QA/en unknown
- 2019-10-14 KR KR1020217014318A patent/KR102923704B1/ko active Active
- 2019-10-14 JP JP2021545267A patent/JP7367038B2/ja active Active
- 2019-10-14 CN CN201980067881.XA patent/CN113260310A/zh active Pending
- 2019-10-14 US US17/285,194 patent/US20210379210A1/en not_active Abandoned
- 2019-10-14 ES ES19872408T patent/ES3037591T3/es active Active
- 2019-10-14 EP EP19872408.0A patent/EP3866692B1/en active Active
- 2019-10-14 WO PCT/US2019/056033 patent/WO2020081410A2/en not_active Ceased
- 2019-10-14 AU AU2019362770A patent/AU2019362770B2/en active Active
- 2019-10-14 CA CA3116129A patent/CA3116129A1/en active Pending
-
2024
- 2024-06-04 US US18/732,745 patent/US20250057995A1/en active Pending
-
2025
- 2025-11-04 US US19/378,556 patent/US20260068185A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022508699A5 (https=) | ||
| US10882860B2 (en) | Treatment of osteoarthritis | |
| JP2019520328A5 (https=) | ||
| JP2019527225A5 (https=) | ||
| AU2014248001A1 (en) | Drug combinations to treat cancer | |
| JPWO2020081410A5 (https=) | ||
| JP7679000B2 (ja) | 新規化合物 | |
| Padma et al. | PET/CT in paediatric malignancies-An update | |
| WO2023240178A1 (en) | Methods of treating cancer with a b-raf inhibitor | |
| Skiöldebrand et al. | Determination of left ventricular mass by computed tomography | |
| Burton et al. | Comparison of bone mineral density in medial coronoid processes of dogs with and without medial coronoid process fragmentation | |
| Padayatty et al. | Octreotide treatment increases exercise capacity in patients with acromegaly | |
| Altunay et al. | Use of radionuclide-based imaging methods in breast cancer | |
| Suhara et al. | Clozapine can induce high dopamine D2 receptor occupancy in vivo | |
| JP6321191B2 (ja) | 腎イメージング剤 | |
| de Vries et al. | Positron emission tomography: measurement of transgene expression | |
| KR102759239B1 (ko) | 암 진단에서 방사성표지된 프로가스트린 | |
| Devaux et al. | Non-invasive evaluation of the cardiac function in golden retriever dogs by radionuclide angiography | |
| AU2010258599B2 (en) | PET imaging of fibrogenesis | |
| JP7688339B2 (ja) | 新規化合物、およびその利用 | |
| Atencio Herre et al. | Comparing Two Folate Receptor β-Targeted Tracers in a Rat Model of Experimental Autoimmune Myocarditis | |
| Valverde et al. | Radiographic imaging of nonhuman primates | |
| WO2026033927A1 (ja) | 卵巣機能の診断剤 | |
| KR20250095627A (ko) | 에스트로겐 수용체-매개 장애의 치료 방법 | |
| WO2018088521A1 (ja) | 肝の糖取込み能評価方法 |